Trial Profile
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Donafenib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 06 Jun 2023 Results of exploratory subgroup analysis (n=668) assessing the OS benefits of donafenib and sorafenib treatment in patients with different short-term response and progression patterns presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2021 Results of exploratory sub-group analysis were presented at the 46th European Society for Medical Oncology Congress.
- 03 Jul 2021 Results (n=333) assessing the correlation between donafenib-related adverse events (AE) and efficacy, presented at the 23rd World Congress on Gastrointestinal Cancer